keyword
https://read.qxmd.com/read/38435499/efficacy-of-dalfampridine-in-neuromyelitis-optica-spectrum-disorder-a-pilot-study
#1
JOURNAL ARTICLE
Jérôme de Seze, Christine Clerc, Matthieu Béreau, Bertrand Bourre, Hélène Zephir, Nicolas Collongues, Laurent Kremer, Patrick Vermersch, Kevin Bigaut
OBJECTIVE: To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder. METHODS: We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests. RESULTS: The mean Timed-25-Foot Walk score was reduced from 14.8 (±2...
2024: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://read.qxmd.com/read/38367309/progression-of-axonal-excitability-abnormalities-with-increasing-clinical-severity-of-diabetic-peripheral-neuropathy
#2
JOURNAL ARTICLE
Roshan Dhanapalaratnam, Tushar Issar, Ann M Poynten, Kerry-Lee Milner, Natalie C G Kwai, Arun V Krishnan
OBJECTIVE: Diabetic peripheral neuropathy (DPN) is a frequent complication for persons with type 2 diabetes. Previous studies have failed to demonstrate any significant impact of treatment for DPN. The present study assessed the role of axonal ion channel dysfunction in DPN and explored the hypothesis that there may be a progressive change in ion channel abnormalities that varied with disease stage. METHODS: Neurophysiological studies were conducted using axonal excitability techniques, a clinical method of assessing ion channel dysfunction...
February 9, 2024: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
https://read.qxmd.com/read/38338871/performance-measures-and-plasma-biomarker-levels-in-patients-with-multiple-sclerosis-after-14-days-of-fampridine-treatment-an-explorative-study
#3
JOURNAL ARTICLE
Maria Thorning, Kate Lykke Lambertsen, Henrik Boye Jensen, Lars Henrik Frich, Jonna Skov Madsen, Dorte Aalund Olsen, Anders Holsgaard-Larsen, Helle Hvilsted Nielsen
Peripheral cytokine levels may serve as biomarkers for treatment response and disease monitoring in patients with multiple sclerosis (pwMS). The objectives were to assess changes in plasma biomarkers in PwMS after 14 days of fampridine treatment and to explore correlations between changes in performance measures and plasma biomarkers. We included 27 PwMS, 14 women and 13 men, aged 52.0 ± 11.6 years, with a disease duration of 17 ± 8.5 years, and an Expanded Disability Status Scale of 6 [IQR 5.0/6...
January 27, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38296293/measuring-and-predicting-the-effect-of-remyelinating-therapy-in-multiple-sclerosis-a-randomised-controlled-trial-protocol-restore
#4
JOURNAL ARTICLE
Sam Hof, Laurentius J van Rijn, Bernard M J Uitdehaag, Jenny A Nij Bijvank, Axel Petzold
INTRODUCTION: Remyelination failure hampers symptomatic recovery in multiple sclerosis (MS), underlining the importance of developing remyelinating therapies. Optic neuritis is currently the most established method of measuring remyelination in MS trials. Complementary more generalisable methods of measuring remyelination are required to confirm treatment efficacy. Measuring internuclear ophthalmoplegia (INO) with infrared oculography provides such a method. Moreover, this method can be expanded with a test for selecting likely treatment responders by using fampridine...
January 30, 2024: BMJ Open
https://read.qxmd.com/read/37567585/ultra-high-performance-liquid-chromatography-method-for-bioanalysis-of-fampridine-using-dried-blood-spot-dbs-methodology-application-to-pharmacokinetic-study-in-albino-rats
#5
JOURNAL ARTICLE
Sheba M K Chalil, Indukala P Chandrasekharan, Singaram Kathirvel, Raja R Katta
Fampridine (dalfampridine) is used to improve walking in people who have multiple sclerosis (a disease in which the nerves do not function properly and may cause weakness, numbness, loss of muscle coordination and problems with vision, speech and bladder control). Measurement of fampridine plasma concentrations is not practical at sites lacking the facilities to prepare and process blood samples. A dried blood spot (DBS) sampling method, in which a few drops of blood, drawn by lancet from the finger, are applied onto specially manufactured absorbent filter paper, can be used as an alternative to plasma monitoring and would allow for simplified sample storage and transport...
August 11, 2023: Journal of Chromatographic Science
https://read.qxmd.com/read/37469336/epidemiological-insights-on-medication-concurrency-and-polypharmacy-in-people-with-multiple-sclerosis-in-greece
#6
JOURNAL ARTICLE
Christos Bakirtzis, Ioannis Nikolaidis, Marina-Kleopatra Boziki, Eleni Grigoriadou, Maria-Valeria Karakasi, Theodoros Moysiadis, Evangelia Kesidou, Georgios Papazisis, Nikolaos Grigoriadis
BACKGROUND: Besides disease-modifying therapies, various pharmacologic agents are frequently prescribed to people with multiple sclerosis (MS) for symptom treatment and for comorbid conditions. The present study aims to investigate the types and frequencies of agents prescribed to people with MS in Greece using records from the nationwide digital prescription database. METHODS: Prescription records for 21,218 people (65.9% women) with MS were included in the study...
2023: International Journal of MS Care
https://read.qxmd.com/read/37462753/functional-connectivity-modifications-in-monoaminergic-circuits-occur-in-fatigued-ms-patients-treated-with-fampridine-and-amantadine
#7
JOURNAL ARTICLE
Maria A Rocca, Paola Valsasina, Maria Teresa Lamanna, Bruno Colombo, Vittorio Martinelli, Massimo Filippi
BACKGROUND: Monoaminergic network dysfunction may have a role in multiple sclerosis (MS) fatigue pathogenesis. OBJECTIVE: To investigate modifications of fatigue severity and resting state (RS) functional connectivity (FC) in monoaminergic networks of 45 fatigued MS patients after different symptomatic treatments. METHODS: Patients were randomly, blindly assigned to fampridine (n = 15), amantadine (n = 15) or placebo (n = 15) treatment and underwent clinical and 3T-MRI evaluations at baseline (t0) and week 4 (w4), i...
July 18, 2023: Journal of Neurology
https://read.qxmd.com/read/37055710/fampridine-for-gait-imbalance-in-patients-with-multiple-sclerosis-ms-a-systematic-review-and-meta-analysis
#8
REVIEW
Sahar Ghorbanpour, Sarvenaz Rahimibarghani, Setareh Rohani, Mohsen Rastkar, Mahsa Ghajarzadeh
BACKGROUND: Gait imbalance is one of the frequent complications in subjects with multiple sclerosis (MS). Fampridine (4-aminopyridine) is a potassium-channel blocker that is administered for gait imbalance in MS. Different studies showed the effects of fampridine on gait status based on various tests in subjects with MS. Some showed significant improvement after treatment, and others did not. So, we designed this systematic review, and meta-analysis to estimate the pooled effects of fampridine on gait status in patients with MS...
September 2023: Neurological Sciences
https://read.qxmd.com/read/37008993/episodic-ataxias-primary-and-secondary-etiologies-treatment-and-classification-approaches
#9
REVIEW
Anhar Hassan
BACKGROUND: Episodic ataxia (EA), characterized by recurrent attacks of cerebellar dysfunction, is the manifestation of a group of rare autosomal dominant inherited disorders. EA1 and EA2 are most frequently encountered, caused by mutations in KCNA1 and CACNA1A . EA3-8 are reported in rare families. Advances in genetic testing have broadened the KCNA1 and CACNA1A phenotypes, and detected EA as an unusual presentation of several other genetic disorders. Additionally, there are various secondary causes of EA and mimicking disorders...
2023: Tremor and Other Hyperkinetic Movements
https://read.qxmd.com/read/36436320/gait-quality-and-function-after-fampridine-treatment-in-patients-with-multiple-sclerosis-a-prospective-cohort-study
#10
JOURNAL ARTICLE
Maria Thorning, Helle Hvilsted Nielsen, Lars Henrik Frich, Henrik Boye Jensen, Kate Lykke Lambertsen, Anders Holsgaard-Larsen
BACKGROUND: Fampridine has shown to improve walking speed, motor control, and balance in patients with multiple sclerosis. However, potential fampridine-induced changes in gait quality and underlying mechanisms, evaluated by three-dimensional gait analysis, are poorly examined. The aim was to examine if two weeks of fampridine treatment would improve gait quality (using Gait Profile Score and Gait Variable Scores from three-dimensional gait analysis) and gait function (using performance-based tests, spatiotemporal parameters, and self-perceived gait function)...
November 17, 2022: Clinical Biomechanics
https://read.qxmd.com/read/36301252/subsecond-three-dimensional-nitrogen-15-magnetic-resonance-imaging-facilitated-by-parahydrogen-based-hyperpolarization
#11
JOURNAL ARTICLE
Alexandra I Trepakova, Ivan V Skovpin, Nikita V Chukanov, Oleg G Salnikov, Eduard Y Chekmenev, Andrey N Pravdivtsev, Jan-Bernd Hövener, Igor V Koptyug
Magnetic resonance imaging (MRI) provides unique information about the internal structure and function of living organisms in a non-invasive way. The use of conventional proton MRI for the observation of real-time metabolism is hampered by the dominant signals of water and fat, which are abundant in living organisms. Heteronuclear MRI in conjunction with the hyperpolarization methods does not encounter this issue. In this work, we polarized 15 N nuclei of [15 N1 ]fampridine (a drug used for the treatment of multiple sclerosis) to the level of 4% in nuclear magnetic resonance (NMR) experiments and 0...
October 27, 2022: Journal of Physical Chemistry Letters
https://read.qxmd.com/read/36094772/fampridine-in-multiple-sclerosis-patients-with-acute-phase-of-cervical-transverse-myelitis-a-double-blind-randomized-placebo-controlled-trial
#12
JOURNAL ARTICLE
Ali Amini Harandi, Hossein Pakdaman, Faezeh Karamiani, Faezeh Mohammadi, Siavash Shirzadeh Barough, Fatemeh Siavoshi, Saba Ilkhani, Mohammadali Sahraian
BACKGROUND: Fampridine is a potassium channel blocker drug used to improve walking ability in patients with multiple sclerosis (MS). We evaluated the effect of fampridine in patients with MS in the acute phase of transverse myelitis. METHODS: In a randomized, placebo-controlled trial, 30 patients who had their first episode of cervical myelitis with quadriparesis presentation, with the final diagnosis of MS, were randomly divided into two equal groups. The intervention group received intravenous methylprednisolone (IVMP) for 7 days plus fampridine...
September 12, 2022: Neurological Sciences
https://read.qxmd.com/read/36090237/improving-detection-of-change-in-motor-functioning-in-multiple-sclerosis-using-video-assisted-composite-measures
#13
JOURNAL ARTICLE
Ka-Hoo Lam, Caspar E P van Munster, Marcus D'Souza, Saskia Steinheimer, Christian P Kamm, Jessica Burggraaff, Matthew Johnson, Yordan Zaykov, Jonas Dorn, Frank Dahlke, Ludwig Kappos, Joep Killestein, Bernard Uitdehaag
BACKGROUND: Assessing motor functioning is important to monitor the disease course of multiple sclerosis (MS). Video-assisted rating of classic neurologic tests and activities of daily living may improve the detection of changes in motor functioning. We investigated the value of using video-assisted composite measures for the detection of changes in mobility and upper extremity function (UEF). METHODS: Forty-three patients with MS were recorded performing motor function tests before and during treatment with fampridine...
September 2022: International Journal of MS Care
https://read.qxmd.com/read/35894120/cost-effectiveness-analysis-of-prolonged-release-fampridine-to-treat-walking-disability-of-multiple-sclerosis-in-china
#14
JOURNAL ARTICLE
Xinran Zhao, Han Yang, Tian Wei, Jin Zhao, Jun Liu, Zhe Huang, Lin Zhu, Yinan Zhao, Wei Li
Objectives: This study evaluates the cost-effectiveness of adding prolonged-release (PR)-fampridine to best supportive care (BSC) versus BSC alone in adult multiple sclerosis patients with walking disability in China. Materials & methods: A hybrid decision tree and Markov model from both the societal and healthcare perspectives were constructed. Parameters were derived from clinical trials of PR-fampridine, published sources and clinical expert interviews. Results: Over a 10-year time horizon, adding PR-fampridine to BSC led to 0...
July 27, 2022: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/35843140/evaluation-of-functional-outcome-measures-after-fampridine-treatment-in-patients-with-multiple-sclerosis-an-interventional-follow-up-study
#15
JOURNAL ARTICLE
Cecilie Dollerup Skov, Christina Borgen Sørensen, Maria Thorning, Kate Lykke Lambertsen, Lars Henrik Frich, Henrik Boye Jensen, Anders Holsgaard-Larsen, Helle H Nielsen
OBJECTIVE: The purpose of this interventional study on participants with multiple sclerosis (MS) with walking disability was to evaluate changes in functional hand and walking measurements after fampridine treatment, after stratifying by the Expanded Disability Status Scale (EDSS). We furthermore wanted to investigate different functional measurements to evaluate their ability to detect responders to fampridine with a clinically relevant improvement. METHODS: Patients were recruited from the MS Clinic at Odense University Hospital and were classified into two disability groups based on their EDSS score (moderate EDSS (EDSSMod ) 4...
October 2022: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/35601756/efficacy-of-prolonged-release-fampridine-versus-placebo-on-walking-ability-dynamic-and-static-balance-physical-impact-of-multiple-sclerosis-and-quality-of-life-an-integrated-analysis-of-mobile-and-enhance
#16
JOURNAL ARTICLE
Raymond Hupperts, Claudio Gasperini, Jan Lycke, Tjalf Ziemssen, Peter Feys, Shan Xiao, Carlos Acosta, Thijs Koster, Jeremy Hobart
Background: MOBILE and ENHANCE were similarly designed randomized trials of walking-impaired adults with relapsing-remitting or progressive multiple sclerosis (MS) who received placebo or 10 mg prolonged-release (PR)-fampridine twice daily for 24 weeks. Both studies showed sustained and clinically meaningful improvement in broad measures of walking and balance over 24 weeks of PR-fampridine treatment. Objective: To evaluate the functional benefits and safety of PR-fampridine versus placebo using a post hoc integrated efficacy analysis of MOBILE and ENHANCE data...
2022: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/35371294/prolonged-release-fampridine-for-the-treatment-of-myoclonus-after-cervical-myelitis-a-case-report
#17
Mona Klara Ros Müller, Monika Christ, Markus Naumann, Antonios Bayas
Prolonged-release fampridine (PR-FAM), a potassium channel blocker, is approved for improving walking ability in patients with multiple sclerosis (MS). Beyond this, positive effects on other MS symptoms like fatigue, cognition, and tremor have been described. To our knowledge, a positive effect of PR-FAM on spinal myoclonus has not been described so far. Here, we report a 32-year-old female with myoclonus after cervical myelitis affecting both hands which markedly improved after administration of PR-FAM. Treatments used before such as carbamazepine or levetiracetam had to be withdrawn because of intolerable side effects or lack of efficacy...
2022: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/35042121/amiloride-is-a-suitable-fluorescent-substrate-for-the-study-of-the-drug-transporter-human-multidrug-and-toxin-extrusion-1-mate1
#18
JOURNAL ARTICLE
Tatsuya Kawasaki, Chisa Kaneko, Ryosuke Nakanishi, Yoshinori Moriyama, Tomohiro Nabekura
Human multidrug and toxin extrusion 1 (MATE1; SLC47A1) is highly expressed in the kidneys and the liver. It plays a significant role in drug and endogenous compound disposition, and therefore, a rapid evaluation of its inhibition is important for drug development and for the understanding of renal and hepatic physiology. Amiloride is a potassium-sparing diuretic used for treating hypertension; it also demonstrates strong fluorescence in organic solvent or detergent solutions. In this study, we investigated the transport characteristics of amiloride by human MATE1...
February 12, 2022: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/34764932/clinical-neurophysiological-and-mri-markers-of-fampridine-responsiveness-in-multiple-sclerosis-an-explorative-study
#19
JOURNAL ARTICLE
Sepehr Mamoei, Henrik Boye Jensen, Andreas Kristian Pedersen, Mikkel Karl Emil Nygaard, Simon Fristed Eskildsen, Ulrik Dalgas, Egon Stenager
Objective: Persons with multiple sclerosis (PwMS), already established as responders or non-responders to Fampridine treatment, were compared in terms of disability measures, physical and cognitive performance tests, neurophysiology, and magnetic resonance imaging (MRI) outcomes in a 1-year explorative longitudinal study. Materials and Methods: Data from a 1-year longitudinal study were analyzed. Examinations consisted of the timed 25-foot walk test (T25FW), six spot step test (SSST), nine-hole peg test (9-HPT), five times sit-to-stand test (5-STS), symbol digit modalities test (SDMT), transcranial magnetic stimulation (TMS) elicited motor evoked potentials (MEP) examining central motor conduction times (CMCT), peripheral motor conduction times (PMCT) and their amplitudes, electroneuronography (ENG) of the lower extremities, and brain structural MRI measures...
2021: Frontiers in Neurology
https://read.qxmd.com/read/34568200/lack-of-attention-to-the-administration-of-fampridine-as-a-symptomatic-drug-in-iranian-multiple-sclerosis-patients
#20
JOURNAL ARTICLE
Abdorreza Naser Moghadasi
No abstract text is available yet for this article.
July 2021: Iranian Journal of Public Health
keyword
keyword
44475
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.